A Day Up For Hepion Pharmaceuticals, Inc.

Thu, Jan 23, 2025 at 07:30 PM
A Day Up For Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals, Inc. (HEPA:NASDAQ) jumped higher at $0.2, a gain of 48.1%. The stock got featured on our News Catalysts scanner on Wed, Jan 22, 2025 at 10:30 AM in the 'PUBLIC OFFERING' category. From Fri, Jan 10, 2025, the stock recorded 37.50% Up Days and 33.33% Green Days

About Hepion Pharmaceuticals, Inc. (HEPA:NASDAQ)

ContraVir Pharmaceuticals Inc is a United States-based biopharmaceutical company engaged in the development of targeted pharmaceutical therapies for liver disease. The company focuses on developing two novel oral compounds to treat HBV infection. CRV431 is a cyclophilin inhibitor that targets specific isomerases that play an important role in protein folding in health and in disease. TXL is a nucleotide pro-drug of tenofovir that inhibits hepatitis B viral replication and targets the liver, the reservoir for the hepatitis B virus.

Share
Get Lifetime 50% Off Premium Subscription
$19.99 USD
Limited-Time Discount
$9.99 USD
monthly
Signup 7 Days Trial. No Credit Card Required!
Ever wanted to explore stocks that have recently spiked... stocks moving sideways... gaps... or other trends? You're in the right place! Check StockTreats features.